PharmacoEconomics & Outcomes News 784, p29 - 12 Aug 2017
Treatment patterns and costs for
advanced GC vary in Mexico
Treatment patterns and costs in patients with
advanced or metastatic gastric cancer (GC) vary in
Mexico, according to findings of an Eli Lilly and
Company-affiliated chart review published in
PharmacoEconomics - Open.
Investigators reviewed Data Report File data for
180 adult patients at three tertiary centres who were
diagnosed with advanced or metastatic GC between
January 2009 and January 2015, received a first-line
fluoropyrimidine and platinum regimen, and were
followed up for at least 3 months after discontinuing
first-line treatment. Direct medical costs were estimated
from a payer perspective.
In total, 16 first-line chemotherapy regimens and
19 second-line regimens were used. Overall, 83.9% of
patients received second-line chemotherapy, 28.3%
received third-line chemotherapy, and less than 10% of
patients received over three lines of chemotherapy.
Supportive care during in first- versus second-line
chemotherapy included pain treatment (12.2% vs 7.9%),
nutritional support (3.3% vs 1.3%), radiotherapy (6.1%
vs 16.6%) and transfusions (13.3% vs 10.6%).
Based on Mexican Institute of Social Security tariffs,
the average total direct cost for first-line and second-line
therapy was $1230
and $1192 per patient-month,
respectively, primarily due to administration costs and
drug acquisition costs.
"Understanding GC treatment patterns in Mexico will
help measure the impact of new innovations in
treatment practice and create opportunities to
harmonize treatment options," said the authors.
* 2015 US dollars
Quintana M, et al. Resources and Costs Associated with the Treatment of
Advanced and Metastatic Gastric Cancer in the Mexican Public Sector: A Patient
Chart Review. PharmacoEconomics-Open : 31 Jul 2017. Available from: URL:
PharmacoEconomics & Outcomes News 12 Aug 2017 No. 7841173-5503/17/0784-0001/$14.95 Adis © 2017 Springer International Publishing AG. All rights reserved